ClinConnect ClinConnect Logo
Search / Trial NCT06977932

The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia

Launched by YUANYUAN WU · May 11, 2025

Trial Information

Current as of July 24, 2025

Not yet recruiting

Keywords

Electroacupuncture Randomized Controlled Trial

ClinConnect Summary

This clinical trial is investigating the use of electroacupuncture (a form of acupuncture that uses small electrical currents) as a treatment for trigeminal neuralgia (TN), a painful condition that affects the face. TN can be very challenging to manage, often causing anxiety and impacting a person's overall quality of life. While the standard medication for this condition is carbamazepine, it can have side effects and may not work for everyone. This study aims to see if electroacupuncture can be an effective alternative treatment for people struggling with TN.

To participate in the trial, individuals should be between 18 and 75 years old and currently taking carbamazepine or a similar medication. They must also have a confirmed diagnosis of trigeminal neuralgia. Participants will be expected to give their consent to be part of the study and will need to be able to communicate about their pain. The trial is not yet recruiting participants, so it’s a good idea to keep an eye out for updates if you or someone you know is interested in this treatment option.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants must meet all of the following criteria to be eligible for this study
  • 1. Met the diagnostic criteria for trigeminal neuralgia (TN) as defined in the International Classification of Headache Disorders, 3rd edition (ICHD-3) published by the International Headache Society (IHS) in 2018.
  • 2. Between 18 and 75 years old (inclusive), regardless of gender;
  • 3. Currently prescribed carbamazepine (100-300 mg/day) or oxcarbazepine (200-600 mg/day);
  • 4. Conscious, alert, and capable of perceiving/differentiating pain, with basic communication abilities;
  • 5. Signed informed consent form and voluntary participation in the study.
  • Exclusion Criteria:
  • Patients meeting any of the following criteria were excluded
  • 1. Patients with epilepsy, head injury, or other relevant neurological disorders;
  • 2. Patients with severe cardiac, hepatic, or renal impairment;
  • 3. Patients with cognitive dysfunction, aphasia, psychiatric disorders, or those unable to cooperate with treatment;
  • 4. Patients with poorly controlled hypertension or hyperglycemia;
  • 5. Patients with a recent diagnosis of severe anxiety or depression;
  • 6. Pregnant or breastfeeding patients;

About Yuanyuan Wu

Yuanyuan Wu is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and a comprehensive understanding of regulatory requirements, Wu leads initiatives that prioritize safety, efficacy, and ethical standards in clinical trials. By fostering collaboration among multidisciplinary teams, she ensures the successful design, execution, and management of trials across various therapeutic areas. Her expertise and leadership contribute significantly to the development of groundbreaking treatments that address unmet medical needs.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported